European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia

SGLT2 inhibitor improves health status in HFrEF

3' education - Nov. 17, 2019 - Mikhail Kosiborod, Kansas City - AHA 2019, Philadelphia
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS

3' education - Feb. 8, 2019

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Complexities of managing heart failure

10' education - Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

10' education - May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague

High risk for poor outcomes in patients with HF hospitalized for COVID-19

Literature - Jan. 22, 2021 - Alvarez-Garcia J, et al. - J Am Coll Cardiol. 2020

Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.

In older patients hospitalized for HF, prevalence of polypharmacy is high

Literature - Dec. 10, 2020 - Unlu O, et al. - Circ Heart Fail 2020

Findings of a study using real-world data from REGARDS showed that prevalence of polypharmacy, defined as ≥10 medications, is high in older patients hospitalized for HF.

COVID-19 and HFpEF

News - Dec. 10, 2020
This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.

This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD
Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD
Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.

Reduction of total HF hospitalizations by IV ferric carboxymaltose in patients with acute HF and iron deficiency

News - Nov. 26, 2020

AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.

CV risk factors and biomarkers are similarly associated with incident HF in men and women

Literature - Oct. 22, 2020 - Suthahar N, et al. - J Am Coll Cardiol. 2020

HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD
Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

Risk reduction for CV death or HF hospitalization with another SGLT2i in HFrEF

News - Sep. 9, 2020

ESC 2020 The EMPEROR-Reduced trial showed that empagliflozin reduced the risk of CV death or HF hospitalization by 25% in HFrEF patients with or without diabetes, compared to placebo.

Reduction of CV death or hospitalization by SGLT2i in HFrEF

News - Aug. 19, 2020

Results from the EMPEROR-Reduced trial showed that the SGLT2 inhibitor empagliflozin significantly reduced the risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes.

Increased risk of adverse outcomes in HFmrEF with LVEF deterioration into midrange

Literature - July 29, 2020 - Brann A et al., - JAMA Cardiol. 2020.

Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.

Comprehensive disease-modifying pharmacological therapies reduce CV events in HFrEF

Literature - July 1, 2020 - Vaduganathan M et al., - The Lancet. 2020.

This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.